Literatur: Bivalirudin

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Bivalirudin

  • 1. Capranzano P, Dangas G., Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial. Expert Rev Cardiovasc Ther. 2012 Apr;10(4):411-22. [PubMed 22458574]
  • 2. Allie DE, Lirtzman MD, Wyatt CH, et al, “Bivalirudin as a Foundation Anticoagulant in Peripheral Vascular Disease: A Safe and Feasible Alternative for Renal and Iliac Interventions," J Invasive Cardiol, 2003, 15(6):334-42. [PubMed 12777673]
  • 3. Anderson JL, Adams CD, Antman EM, et al, “ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,” J Am Coll Cardiol, 2007, 50(7):1-157. [PubMed 17692738]
  • 4. Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation, 2004, 110(5):588-636. [PubMed 15289388]
  • 5. Antman EM, “Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?” JAMA, 2003, 289:903-5. [PubMed 12588276]
  • 6. Aggarwal A, Sobel BE, and Schneider DJ, “Decreased Platelet Reactivity in Blood Anticoagulated With Bivalirudin or Enoxaparin Compared With Unfractionated Heparin: Implications for Coronary Intervention,” J Thromb Thrombolysis, 2002, 13:161-5. [PubMed 12355033]
  • 7. Bittl JA, Chaitman BR, Feit F, et al, “Bivalirudin Versus Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina: Final Report Reanalysis of the Bivalirudin Angioplasty Study,” Am Heart J, 2001, 142:952-9. [PubMed 11717596]
  • 8. Bittl JA, Strony J, Brinker JA, et al, “Treatment With Bivalirudin (Hirulog) as Compared With Heparin During Coronary Angioplasty for Unstable or Postinfarction Angina. Hirulog Angioplasty Study Investigators,” N Engl J Med, 1995, 333(12):764-9. [PubMed 7643883]
  • 9. Dager WE, Dougherty JA, Nguyen PH, et al, “Heparin-Induced Thrombocytopenia: Treatment Options and Special Considerations,” Pharmacotherapy, 2007, 27(4):564-87. [PubMed 17381384]
  • 10. Dangas GD, Mehran R, Nikolsky E, et al, “Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction: The HORIZONS-SWITCH Analysis,” J Am Coll Cardiol, 2001, 57(23):2309-11. [PubMed 21636031]
  • 11. Davis Z, Anderson R, Short D, et al, “Favorable Outcome With Bivalirudin Anticoagulation During Cardiopulmonary Bypass,” Ann Thorac Surg, 2003, 75(1):264-5. [PubMed 12537226]
  • 12. Dyke CM, Aldea G, Koster A, et al, “Off-Pump Coronary Artery Bypass With Bivalirudin for Patients With Heparin-Induced Thrombocytopenia or Antiplatelet Factor Four/Heparin Antibodies,” Ann Thorac Surg, 2007, 84(3):836-40. [PubMed 17720385]
  • 13. Dyke CM, Smedira NG, Koster A, et al, “A Comparison of Bivalirudin to Heparin With Protamine Reversal in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: The EVOLUTION-ON Study,” J Thorac Cardiovasc Surg, 2006, 131(3):533-9. [PubMed 16515902]
  • 14. Fuchs J and Cannon CP, “Hirulog in the Treatment of Unstable Angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 Trial,” Circulation, 1995, 92(4):727-33. [PubMed 7641350]
  • 15. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 16. Kiser TH and Fish DN, “Evaluation of Bivalirudin Treatment for Heparin-Induced Thrombocytopenia in Critically Ill Patients With Hepatic and/or Renal Dysfunction,” Pharmacotherapy, 2006, 26(4):452-60. [PubMed 16553502]
  • 17. Kiser TH, Burch JC, Klem PM, et al, “Safety, Efficacy, and Dosing Requirements of Bivalirudin in Patients With Heparin-induced Thrombocytopenia,” Pharmacotherapy, 2008, 28(9):1115-24. [PubMed 18752382]
  • 18. Koster A, Chew D, Grundel M, et al, “An Assessment of Different Filter Systems for Extracorporeal Elimination of Bivalirudin: An In Vitro Study,” Anesth Analg, 2003, 96(5):1316-19. [PubMed 12707125]
  • 19. Koster A, Chew D, Grundel M, et al, “Bivalirudin Monitored With the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary Bypass,” Anesth Analg, 2003, 96(2): 383-6. [PubMed 12538181]
  • 19. Koster A, Dyke CM, Aldea G, et al, “Bivalirudin During Cardiopulmonary Bypass in Patients With Previous or Acute Heparin-Induced Thrombocytopenia and Heparin Antibodies: Results of the CHOOSE-ON Trial,” Ann Thorac Surg, 2007, 83(2):572-7. [PubMed 17257990]
  • 20. Koster A, Spiess B, Chew DP, et al. “Effectiveness of Bivalirudin as a Replacement for Heparin During Cardiopulmonary Bypass in Patients Undergoing Coronary Artery Bypass Grafting,” Am J Cardiol, 2004, 93(3):356-9. [PubMed 14759391]
  • 21. Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
  • 22. Lincoff AM, Bittl JA, Harrington RA, et al, “Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. REPLACE-2 Randomized Trial,” JAMA, 2003, 289(7):853-63. [PubMed 12588269]
  • 23. Lincoff AM, Kleiman NS, Kereiakes DJ, et al, “Long-Term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization: REPLACE-2 Randomized Trial,” JAMA, 2004, 292(6):696-703. [PubMed 15304466]
  • 24. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al, “Bivalirudin With Planned or Provisional Abciximab Versus Low-Dose Heparin and Abciximab During Percutaneous Coronary Revascularization: Results of the Comparison of Abciximab Complications With Hirulog for Ischemic Events Trial (CACHET),” Am Heart J, 2002, 143(5):847-53. [PubMed 12040347]
  • 25. Linkins L, Dans AL, Moores LK, et al, “Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):e495-530. [PubMed 22315270]
  • 26. Merry AF, Raudkivi PJ, Middleton NG, et al, “Bivalirudin Versus Heparin and Protamine in Off-Pump Coronary Artery Bypass Surgery,” Ann Thorac Surg, 2004, 77:925-31. [PubMed 14992900]
  • 27. Neuhaus KL, Molhoek GP, Zeymer U, et al, “Recombinant Hirudin (Lepirudin) for the Improvement of Thrombolysis With Streptokinase in Patients With Acute Myocardial Infarction: Results of the HIT-4 Trial,” J Am Coll Cardiol, 1999, 34(4):966-73. [PubMed 10520777]
  • 28. Robson R, “The Use of Bivalirudin in Patients With Renal Impairment,” J Invasive Cardiol, 2000, 12:33F-36F. [PubMed 11156732]
  • 29. Shammas NW, Lemke JH, Dippel EJ, et al, “Bivalirudin in Peripheral Vascular Interventions: A Single Center Experience,” J Invasive Cardiol, 2003, 15(7):401-4. [PubMed 12840239]
  • 30. Smedira NG, Dyke CM, Koster A, et al, “Anticoagulation With Bivalirudin For Off-Pump Coronary Artery Bypass Grafting: The Results Of The EVOLUTION-OFF Study,” J Thorac Cardiovasc Surg, 2006, 131(3):686-92. [PubMed 16515924]
  • 31. Stone GW, McLaurin BT, Cox DA, et al, “Bivalirudin for Patients With Acute Coronary Syndromes,” N Engl J Med, 2006, 355(21):2203-16. [PubMed 17124018]
  • 32. Stone GW, Witzenbichler B, Guagliumi G, et al, “Bivalirudin During Primary PCI in Acute Myocardial Infarction,” N Engl J Med, 2008, 358(21):2218-30. [PubMed 18499566]
  • 33. Tsu LV and Dager WE, “Bivalirudin Dosing Adjustments for Reduced Renal Function With or Without Hemodialysis in the Management of Heparin-Induced Thrombocytopenia,” Ann Pharmacother, 2011, 45(10):1185-92. [PubMed 21881032]
  • 34. Vasquez JC, Vichiendilokkul A, Mahmood S, et al, “Anticoagulation With Bivalirudin During Cardiopulmonary Bypass in Cardiac Surgery,” Ann Thorac Surg, 2002, 74(6):2177-9. [PubMed 12643418]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun